Lactobacillus salivarius for Health & Longevity - Quick Reference Sheet

Lactobacillus salivarius for Health & Longevity

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

Lactobacillus salivarius is a bacterium used in probiotic supplements for oral, digestive and other health goals. Selected preparations have the strongest evidence for preventing breast inflammation during breastfeeding and reducing eczema severity. Benefits depend on the strain and condition; oral results are inconsistent. Short-term tolerance is generally favorable, but allergies and infection risk matter. Routine supplementation has not been shown to slow human aging or extend life. (Full Review)

Protocol

Intestinal regimen:
CECT5713: 200 million viable bacteria daily
Daily oral capsule for four weeks; strain-specific study dose, not a minimum for other products.
Mastitis-prevention regimen:
PS2: ~1 billion viable bacteria daily
Once daily, gestational week 35 through 12 weeks after delivery; prevention research.
Oral-health regimen:
WB21: 670 million viable bacteria, 3 times daily
Eight weeks. Oral-contact tablets after meals, allowed to dissolve in the mouth.
Time to effect
Reduced Eczema Severity
8–16 weeks
Studied assessment interval.
Fewer Gout Episodes
6 months
CECT30632 pilot assessment.
Fertility Outcomes in Unexplained Infertility
Several months
Specialist assisted-reproduction setting.

Benefits

Contraindications
  • Known allergy to the exact product or its ingredients
  • Predicted severe acute pancreatitis
  • Severe immune suppression, active intensive-care illness, an indwelling central venous catheter, or major intestinal-barrier disruption outside a specialist-supervised indication
  • Premature infants outside an explicitly supervised neonatal protocol
Key Interactions
  • Antibiotics (amoxicillin, doxycycline)
  • Immune-suppressing medicines (tacrolimus, mycophenolate, high-dose prednisone); cytotoxic treatment (cyclophosphamide)
  • Cancer immunotherapy (pembrolizumab, nivolumab)
  • Oral antiseptics (chlorhexidine, cetylpyridinium)
  • Fiber supplements (inulin, fructo-oligosaccharides)
  • Other probiotic supplements
  • Disease treatment: substitution for needed dental care, urate-lowering treatment, antibiotics, or maternity infection prevention

Risk & Side Effects

  • High:
  • Medium:
  • Low: Death and Bowel Injury During Severe Pancreatitis; Gastrointestinal Discomfort; Invasive Infection in Susceptible Hosts; Allergy to Product Ingredients; Reduced Response to Cancer Immunotherapy
  • Speculative: Enhanced Pathogen Activity in Experimental Models; Transfer of Undesirable Bacterial Traits; Strain-Dependent Tooth Decay

Monitoring

Marker Target Why
Oral inflammation and pocket depthNo probiotic-specific optimal range; change from baselineMeasure oral outcome
Eczema severity scoreNo probiotic-specific target; change from baselineMeasure skin outcome
Serum urate, only for established goutNo probiotic-specific functional range; baseline change against clinician’s disease targetFollow gout biology
Blood count, chemistry, or inflammatory testsNo established routine target; clinically indicated abnormalitiesInvestigate illness
Stool or oral species abundanceNo established healthy or optimal L. salivarius range; clinical change is the endpointLimited research utility; routine serial testing has no demonstrated value

Cadence: Baseline; tolerance at 1–2 weeks; oral/intestinal outcomes at 4–8 weeks; eczema at 8–16 weeks; other indications at their study interval. No validated laboratory panel or commercial microbiome range.

Qualitative Assessment

  • Symptoms: Breath concerns, bowel frequency, skin discomfort or selected symptom. Function: Daily comfort and usual activities. Adverse effects: New digestive symptoms, rash, fever or worsening illness.